Cargando…
Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients
PURPOSE: Survival among patients with adenocarcinoma pancreatic cancer (PDCA) is highly variable, which ranges from 0% to 20% at 5 years. Such a wide range is due to tumor size and stage, as well other patients' characteristics. We analyzed alterations in the metabolomic profile, of PDCA patien...
Autores principales: | Fontana, Andrea, Copetti, Massimiliano, Di Gangi, Iole Maria, Mazza, Tommaso, Tavano, Francesca, Gioffreda, Domenica, Mattivi, Fulvio, Andriulli, Angelo, Vrhovsek, Urska, Pazienza, Valerio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891018/ https://www.ncbi.nlm.nih.gov/pubmed/26840268 http://dx.doi.org/10.18632/oncotarget.7108 |
Ejemplares similares
-
Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites
por: Di Gangi, Iole Maria, et al.
Publicado: (2016) -
Early-Onset Diabetes as Risk Factor for Pancreatic Cancer: miRNA Expression Profiling in Plasma Uncovers a Role for miR-20b-5p, miR-29a, and miR-18a-5p in Diabetes of Recent Diagnosis
por: Tavano, Francesca, et al.
Publicado: (2020) -
Clinical Significance of Circulating miR-1273g-3p and miR-122-5p in Pancreatic Cancer
por: Mazza, Tommaso, et al.
Publicado: (2020) -
MicroRNA co-expression networks exhibit increased complexity in pancreatic ductal compared to Vater's papilla adenocarcinoma
por: Mazza, Tommaso, et al.
Publicado: (2017) -
Correlations among PPARγ, DNMT1, and DNMT3B Expression Levels and Pancreatic Cancer
por: Pazienza, Valerio, et al.
Publicado: (2012)